The Senate Finance Committee has released a detailed report of its investigations into how the Food and Drug Administration and GlaxoSmithKline handled research into whether the diabetes drug Avandia increases the risk of heart attacks. Neither the FDA nor Glaxo comes out looking very good. A press release, the report, and a letter Senators Charles Grassley and Max Baucus sent to the FDA can all be found here. A New York Times story on differences of opinion detailed in the report is here.
via blogs.forbes.com
No comments:
Post a Comment